Color: Jill Hagenkord
Jill Hagenkord is no longer chief medical officer of genetic testing firm Color and has started a new consulting company called MDisrupt. Hagenkord previously held executive positions at Invitae, 23andMe, and Complete Genomics. She co-founded MDisrupt with another 23andMe alum, Ruby Gadelrab, who is serving as CEO. The start-up describes itself as a "medical diligence company" that aims to help companies speed innovative products to market by "assessing a product's clinical and commercial viability in a healthcare setting."
PerkinElmer: Robert Friel, Prahlad Singh, Alexis Michas
After serving 12 years as CEO of PerkinElmer, Robert Friel will step down from the position as well as from his role as chairman of the board, effective Dec. 29. He will continue to serve as an advisor until Mar. 1, 2020. The firm also announced that Prahlad Singh, current president and chief operating officer of PerkinElmer, will become CEO on Dec. 30, and he has been elected a director of the company, effective Aug. 21. Prior to joining PerkinElmer in 2014, Singh served as general manager of GE Healthcare's women's health business.
PerkinElmer also said that Alexis Michas, currently lead director, will serve as non-executive chairman of PerkinElmer's board, starting Dec. 30.
Tempus: Joel Dudley
Tempus has appointed Joel Dudley as senior VP of research. Dudley previously was executive VP for precision health at Mount Sinai Health System and founding director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.